74 completed, 16 terminated, 4 unknown, 3 withdrawn. 30 Phase 4, 24 Phase 2, 22 Phase 3, 11 Not applicable, 10 Phase 1.
Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer Paricalcitol, pirfenidone - Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma | Phase 2 | Not yet recruiting | Patrick Wagner, MD, FACS | 74 | 2026-09-01 | 2026-10-05 |
| The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients Paricalcitol injection, Placebo - Sepsis | Not applicable | Not yet recruiting | University of Split, School of Medicine | 90 | 2025-05-01 | 2024-12-06 |
| A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis Paricalcitol, Placebo - Chronic Pancreatitis | Early Phase 1 | Active not recruiting | Cedars-Sinai Medical Center | 24 | 2023-06-01 | 2026-08-05 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism Paricalcitol, Placebo - Secondary Hyperparathyroidism | Phase 3 | Unknown | Chengdu Suncadia Medicine Co., Ltd. | 84 | 2022-02-01 | 2022-02-10 |
| PHL Treatment in Pancreatic Cancer Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control) - Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Active not recruiting | Fox Chase Cancer Center | 20 | 2021-10-20 | 2026-05-22 |
| Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Paricalcitol, Gemcitabine (GEM) and Nab-paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Completed | Cancer Trials Ireland | 15 | 2020-10-16 | 2024-03-06 |
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) Paricalcitol - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | Phase 3 | Terminated | AbbVie | 2 | 2020-09-16 | 2026-06-15 |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer Gemcitabine, Hydroxychloroquine, Nab-paclitaxel - Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | Emory University | 10 | 2020-09-14 | 2026-01-23 |
| A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer Nivolumab, Nab-Paclitaxel, Gemcitabine - Pancreatic Cancer | Early Phase 1 | Terminated | Abramson Cancer Center at Penn Medicine | 3 | 2020-07-29 | 2024-03-15 |
| Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy 5-FU, Leucovorin, Liposomal Irinotecan - Pancreatic Cancer, Pancreas Cancer | Phase 1 | Completed | Washington University School of Medicine | 20 | 2019-07-11 | 2022-10-05 |
| Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer Gemcitabine, Nab-paclitaxel, Paricalcitol - Pancreatic Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 36 | 2018-12-05 | 2025-03-21 |
| Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Paclitaxel protein bound, Cisplatin, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Barts & The London NHS Trust | 27 | 2018-11-29 | 2025-11-21 |
| Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol - Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency | Phase 4 | Completed | OPKO Health, Inc. | 69 | 2018-06-08 | 2022-12-09 |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Paricalcitol (Zemplar) - Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 34 | 2018-01-31 | 2026-05-12 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Pembrolizumab, paricalcitol, placebo - Pancreatic Cancer, Pancreas Adenocarcinoma | Phase 2 | Completed | Translational Genomics Research Institute | 24 | 2017-12-27 | 2022-12-27 |
| A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Paricalcitol - Pancreatic Cancer | Phase 1 | Terminated | Abramson Cancer Center at Penn Medicine | 3 | 2017-09-28 | 2022-03-31 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Paclitaxel Protein Bound (Abraxane) - Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 2 | Completed | HonorHealth Research Institute | 40 | 2017-05-23 | 2026-04-22 |
| Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel - Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7 | Phase 1 | Completed | M.D. Anderson Cancer Center | 9 | 2017-02-20 | 2023-02-09 |
| Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Nivolumab, Albumin-bound paclitaxel, Paricalcitol - Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 35 | 2016-04-01 | 2025-08-27 |
| DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. Paricalcitol, Placebo (for paricalcitol) - Hypersensitivity | Phase 2 | Completed | Laurian Jongejan | 44 | 2015-10-01 | 2018-09-04 |
Showing 20 of 102. Sign in to see all of them.
Renal Insufficiency, Chronic (36) · Hyperparathyroidism, Secondary (33) · Kidney Failure, Chronic (15) · Pancreatic Neoplasms (8) · Hyperparathyroidism (7) · Kidney Diseases (6) · Proteinuria (5) · Vitamin D Deficiency (5) · Hypercalcemia (4) · Hypertrophy, Left Ventricular (3) · Renal Insufficiency (3) · Albuminuria (2) · Anemia (2) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 2 (2)
Abbott (22) · AbbVie (prior sponsor, Abbott) (6) · Abramson Cancer Center at Penn Medicine (3) · HonorHealth Research Institute (3) · Wake Forest University Health Sciences (3) · Cedars-Sinai Medical Center (2) · Federico II University (2) · Genzyme, a Sanofi Company (2) · Indiana University (2) · Mario Negri Institute for Pharmacological Research (2) · OPKO Health, Inc. (2) · Roswell Park Cancer Institute (2) · The University of Hong Kong (2) · Washington University School of Medicine (2) · Winthrop University Hospital (2)
United States (58) · Italy (8) · Spain (8) · Poland (7) · Germany (5) · Japan (5) · Denmark (4) · Greece (4) · Netherlands (4) · Puerto Rico (4) · Russia (4) · United Kingdom (4) · Czechia (3) · Hong Kong (3) · Taiwan (3)
Laura Williams, M.D. (4) · Ann Eldred, MD (3) · Erkut Borazanci, MD (3) · Peter O'Dwyer, MD (3) · Dennis Andress, MD (2) · Rajiv Agarwal, MD (2) · Alan Lau, PharmD (1) · Alexander Kharlamov, M.D. (1) · Alexander Perrish, M.D. (1) · Alp Ikizler, MD (1) · Amy Pai, Pharm.D. (1) · Amy Pai, PharmD (1)
PMID 18591942, PMID 28332096, PMID 18606901, PMID 19596163, PMID 19778452, PMID 21055801, PMID 21242674, PMID 21716260, PMID 22166847, PMID 22237748, PMID 22337679, PMID 22387567, PMID 22839442, PMID 22913981, PMID 22997344, PMID 23194491, PMID 23311404, PMID 23787544, PMID 23889806, PMID 24052631, PMID 24214232, PMID 24500308, PMID 24970869, PMID 25029424, PMID 25112372, PMID 25781618, PMID 26496210, PMID 27402170, PMID 28511692, PMID 29104158, PMID 29386411, PMID 30062716, PMID 30134956, PMID 30691124, PMID 31370809, PMID 32775985, PMID 33326471, PMID 33772369, PMID 34359984, PMID 35022790, PMID 36645291, PMID 39698346, PMID 39730001, PMID 39846984, PMID 41535788, PMID 42185478, PMID 42268676
2009 (3), P30CA012197 (2), 2008 (1), P30CA138292 (1), P50AR054086 (1), R01DK132631 (1), R21CA252535 (1)